Chromatin remodeling gene mutations were identified in 9 of 17 tumors (53%), involving BAP1 mutations in 6 tumors (35%), SETD2 mutations in 4 tumors (24%), and an ARID1A mutation in 1 tumor (6%). This evidence concerns the gene SETD2 and neoplasm.